1. Home
  2. BWMX vs OMER Comparison

BWMX vs OMER Comparison

Compare BWMX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BWMX
  • OMER
  • Stock Information
  • Founded
  • BWMX 1995
  • OMER 1994
  • Country
  • BWMX Mexico
  • OMER United States
  • Employees
  • BWMX N/A
  • OMER N/A
  • Industry
  • BWMX Catalog/Specialty Distribution
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • BWMX Consumer Discretionary
  • OMER Health Care
  • Exchange
  • BWMX Nasdaq
  • OMER Nasdaq
  • Market Cap
  • BWMX 354.5M
  • OMER 397.1M
  • IPO Year
  • BWMX N/A
  • OMER 2009
  • Fundamental
  • Price
  • BWMX $7.92
  • OMER $3.09
  • Analyst Decision
  • BWMX Strong Buy
  • OMER Buy
  • Analyst Count
  • BWMX 1
  • OMER 4
  • Target Price
  • BWMX $22.50
  • OMER $22.50
  • AVG Volume (30 Days)
  • BWMX 55.0K
  • OMER 1.4M
  • Earning Date
  • BWMX 07-24-2025
  • OMER 05-15-2025
  • Dividend Yield
  • BWMX 16.07%
  • OMER N/A
  • EPS Growth
  • BWMX N/A
  • OMER N/A
  • EPS
  • BWMX 0.74
  • OMER N/A
  • Revenue
  • BWMX $684,841,453.00
  • OMER N/A
  • Revenue This Year
  • BWMX $4.90
  • OMER N/A
  • Revenue Next Year
  • BWMX $6.07
  • OMER $2,447.88
  • P/E Ratio
  • BWMX $10.64
  • OMER N/A
  • Revenue Growth
  • BWMX 4.87
  • OMER N/A
  • 52 Week Low
  • BWMX $7.00
  • OMER $2.97
  • 52 Week High
  • BWMX $17.50
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • BWMX 23.16
  • OMER 26.94
  • Support Level
  • BWMX $7.00
  • OMER $3.00
  • Resistance Level
  • BWMX $8.90
  • OMER $3.34
  • Average True Range (ATR)
  • BWMX 0.52
  • OMER 0.49
  • MACD
  • BWMX -0.10
  • OMER -0.00
  • Stochastic Oscillator
  • BWMX 31.83
  • OMER 4.10

About BWMX Betterware de Mexico S.A.P.I. de C.V.

Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided in seven categories of the home organization: Kitchen and food preservation, Home solutions, Bedroom, Bathroom, Laundry & Cleaning, Tech & mobility and wellness. The JAFRA's segment is divided into four categories beauty and personal care: fragrance, color (cosmetics), skin care and toiletries. The company generates a majority of its revenue from the Beauty and personal care (B&PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: